Responses
Regular and young investigator award abstracts
Clinical trials in progress
373 Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2
Compose a Response to This Article
Other responses
No responses have been published for this article.
